Raman chemical imaging
September 18th: Spectral Analysis of Materials using Raman Chemical Imaging
This webinar is designed for professionals (e.g. Quality Control, Industrial Engineers) involved in the production and development of various materials, ranging from adhesives and polymers to plastics and glass. During this webinar, we will discuss how Raman chemical imaging can be beneficial for analyzing this types of materials and how it can improve product development and failure analysis [...]
David Exline, Senior Vice President
David Exline has more than 15 years of experience in managing and administering analytical laboratory and consulting services. As Senior Vice President of Gateway Analytical, he oversees the company’s day-to-day operations, business growth and service areas.
Antonio Scatena, Laboratory Manager
Antonio has worked at Gateway Analytical for almost 3 years, and has over 5 years experience in the pharmaceutical service, pharmaceutical forensic, criminal forensic, and materials science industries.
Oksana Olkhovyk, Ph.D., Senior Scientist
Dr. Oksana Olkhovyk plays an important role supporting analytical testing services within Gateway Analytical cGMP and ISO-based quality assurance laboratories for the pharmaceutical, materials science and forensics industries. She has over 10 years experience in Raman spectroscopy, imaging and material characterization and serves as a scientific liaison between Gateway Analytical and their customers, as well as academic and industrial collaborators.
Working to Address the Critical Path Opportunity for Generic Nasal Spray Suspensions
This webinar is designed for generic drug manufacturers of nasal spray suspensions. During this webinar, our presenters will discuss how the method of Ingredient-Specific Particle Sizing (ISPS) using Raman Chemical Imaging (RCI) developed by Gateway Analytical, can address the critical path opportunity by providing the accurate and precise drug particle size measurement to demonstrate bioequivalence. Using this method, generic nasal spray suspension developers have the potential to save considerable time and money by waiving the in vivo biostudies.
